Pharmaceutical composition for treating acute kidney injury

A pharmaceutical composition, kidney injury technology, applied in the directions of drug combination, drug delivery, pharmaceutical formulation, etc., can solve the problems of ineffective treatment of stem cells, consumption of medical resources, inability to treat kidney damage, etc.

Inactive Publication Date: 2018-07-13
GWOXI STEM CELL APPL TECH CO LTD
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Currently, the treatment methods for acute kidney injury are mainly hemodialysis, renal replacement therapy or supportive therapy, but they all consume a lot of medical resources and cannot effectively treat kidney injury. Researches in this field all point to new treatments based on adipose-derived stem cells or other types of stem cells; however, some studies have pointed out that if stem cells are used alone as a treatment material, it may be because the kidneys will produce a strong immune response after damage (Immune response), oxidative stress (Oxidative stress) and cell apoptosis (Apoptosis), resulting in the ineffective treatment of stem cells, how to improve this dilemma has become the focus of research in recent years

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating acute kidney injury
  • Pharmaceutical composition for treating acute kidney injury
  • Pharmaceutical composition for treating acute kidney injury

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

[0056] "Preparation Example 1" (Preparation of platelet-rich fibrin release solution)

[0057] First, 10-week-old New Zealand white rabbits (New Zealand White Rabbit, purchased from Weixinhang) were treated with 50 mg / mL of Zoletil ( 50, Virbac, France) and Xylazine at a concentration of 20mg / mL ( Gongyuan Pharmaceuticals, Taiwan) mixed with a 1:1 ratio, intramuscularly injected with a dose of 0.25mL / kg for general anesthesia, so that the white rabbits were sedated and reached a state of shallow anesthesia. Next, the hair near the neck of the rabbit was shaved clean, and the skin of the neck of the rabbit was wiped from the inside to the outside with cotton dipped in a mixture of 10% iodine and 75% ethanol for disinfection.

[0058] After the disinfection is completed, use a 10mL syringe with an 18G needle to collect fresh blood from the external jugular vein in the neck of the rabbit without adding an anticoagulant.

[0059]Immediately transfer the extracted fresh rabbit ...

preparation example 2

[0063] "Preparation Example 2" (Preparation of Adipose Stem Cells)

[0064] First, 8-week-old healthy SD strain rats without any obvious trauma were treated with Zoletil at a concentration of 50 mg / mL ( 50, Virbac, France) and Xylazine at a concentration of 20mg / mL ( Gongyuan Pharmaceuticals, Taiwan) mixed solution in a ratio of 1:1 was injected intramuscularly at a dose of 0.25mL / kg, and the rats were generally anesthetized. Then, the hair at the hind limbs of the rats was shaved, and the skin of the hind limbs of the rats was wiped from the inside to the outside with cotton dipped in a mixture of 10% iodine and 75% ethanol to completely sterilize.

[0065] The sterilized rats were subjected to liposuction under a sterile environment. The adipose tissue extracted from the abdominal cavity of the rat was washed three times with PBS, then added with type I collagenase, and shaken at room temperature for one hour. Centrifuge at 3000 rpm for 10 minutes.

[0066] After centr...

Embodiment 1

[0086] "Example 1" (kidney tissue+PRFr+adipose stem cell R of acute kidney injury)

[0087] First, acute kidney injury kidney tissue homogenate (AKI-KHS) was prepared as an experimental material. The rats after renal ischemia reperfusion (Ischemia Reperfusion, IR) operation were executed and their kidneys were removed. Acute kidney injury tissue homogenate (AKI-KHS), and then the acute kidney injury tissue homogenate (AKI-KHS) was centrifuged at a constant temperature of 4° C. at a speed of 20,000 rpm for 15 minutes. Afterwards, the supernatant was taken out and filtered through a sieve with a pore size of 30 μm to obtain an AKI-HHS filtrate. Finally, put the filtrate into a clean centrifuge tube and store it in a -80°C refrigerator

[0088] Utilizing the characteristics of the upper and lower layers of the Transwell chamber, the adipose stem cell R obtained in "Preparation Example 2" was divided into 4×10 5 The number of cells per well (cells / well) is placed in the lower 6...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
control rateaaaaaaaaaa
control rateaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a pharmaceutical composition for treating acute kidney injury, wherein the pharmaceutical composition comprises stem cells and a platelet-rich fibrin (PRF) release liquid, the stem cells are embryonic stem cells, adult stem cells or induced pluripotent stem cells, and the platelet-rich fibrin release liquid at least contains a growth factor selected from Transforming growth factor-beta1 (TGF-[beta]1), Vascular endothelial growth factor (VEGF), Platelet-derived growth factor (PDGF), Bone morphogenetic protein (BMP), Platelet factor 4 (PF4), Interleukin (IL), Epidermal growth factor (EGF), Fibroblast growth factor (FGF), Nerve growth factor (NGF), and Insulin-like growth factor (IGF).

Description

technical field [0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for treating patients with acute kidney injury. Background technique [0002] Acute kidney injury (Acute kidney injury, AKI) is a common symptom of kidney damage, characterized by acute renal dysfunction. In clinical situations, acute kidney injury will increase the mortality of patients, and even a slight increase in serum creatinine (creatinine) or mild proteinuria will still have an adverse effect on the prognosis of patients. Not only that, patients with acute kidney injury have a higher risk of developing end-stage renal disease (ESRD) in the future and long-term mortality than patients without acute kidney injury. Currently, the incidence of end-stage renal disease in Taiwan Both the rate and prevalence of AKI are the highest in the world, so how to treat AKI has become an important issue. [0003] In order to find an effective and convenient tr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K38/30A61K38/20A61K38/18A61K35/545A61K35/28A61K35/51A61K35/30A61P13/12
CPCA61K9/0019A61K35/28A61K35/30A61K35/51A61K35/545A61K38/1808A61K38/1825A61K38/1841A61K38/185A61K38/1858A61K38/1866A61K38/1875A61K38/20A61K38/30A61K45/06A61K2300/00
Inventor 郭宗甫罗玉翔詹明沄许世源戴裕庭庄明熙林珀丞周宪民
Owner GWOXI STEM CELL APPL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap